---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-017653"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T01:04:21.353664+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q1 rev $837M (+8%); cuts FY22 EPS guidance to $8.11-$8.35 on vet capacity, forex, R&D charge

## Summary
- Q1 EPS $2.27 (-3% reported, +3% comparable); revenue $837M (+8% reported and organic).
- CAG Diagnostics recurring revenue +9% organic; record Q1 premium instrument placements; capital instrument rev +22% organic.
- FY22 revenue outlook cut to $3,390-$3,465 (5.5%-8% reported growth); organic growth 7.5%-10%.
- FY22 EPS outlook $8.11-$8.35 includes $0.72 discrete R&D charge, $0.10 forex, $0.05 interest; prior guidance implied down.
- U.S. same-store clinical visits declined 2% in Q1 vs +13% prior year; practice revenue +6% vs +16%.

## SEC filing metadata
- accession: 0001564590-22-017653
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000156459022017653/0001564590-22-017653-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000156459022017653/idxx-8k_20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-017653
- JSON: https://secwatch.observer/filing/0001564590-22-017653.json
- Plain text: https://secwatch.observer/filing/0001564590-22-017653.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.